Clinical Trials Team

The Clinical Trials Research Team within the Department of Pharmacotherapy is based at WSU Spokane and led by Dr. Carol Wysham and Pharmacist Joshua Neumiller. They conduct clinical trials centered on the management of diabetes and its complications. The goals of the clinical research team are to conduct high-quality clinical research as a means to provide hands-on diabetes care to members of the greater Spokane community, and to improve the management and outcomes achieved for people with diabetes. If you have questions about any of our current studies, or think you might be interested in participating in clinical research, please contact Debbie Weeks.

Active Clinical Studies

EXSCEL

Participant recruitment is closed.

The EXSCEL Trial, EXenatide Study of Cardiovascular Event Lowering Trial, is a long term clinical trial examining the effects of once-weekly exenatide on lowering cardiovascular events compared to a placebo (inactive agent). People with type 2 diabetes that are on oral diabetes medications may qualify. There are other inclusion and exclusion that apply. As a participant you will be followed closely and optimal diabetes control will be encouraged. Optional nutrition and activity education will be offered.

This once weekly formulation of exenatide was recently approved by the FDA under the brand name “Bydureon.”

LEADER

Participant recruitment is closed, study still active.

The LEADER Trial, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results is a long term clinical trial examining the effects of liraglutide (Victoza) on cardiovascular outcomes compared to a placebo (inactive agent). People with type 2 diabetes that are on oral medications and long acting insulin may qualify. There are other inclusions and exclusions that apply. As a participant you will be followed closely and optimal diabetes control will be encouraged.

Liraglutide (Victoza) is FDA approved.

CANVAS

Participant recruitment is closed, study still active.

The CANVAS Trial, CANagliflozin cardioVAScular Assessment Study, is a long term clinical trial examining the effects of canagliflozin on cardiovascular outcomes compared to placebo (inactive agent). Canagliflozin is an investigational agent that works on the kidneys to lower blood glucose levels, weight and blood pressure.

EUCLID

Participant recruitment is closed, study still active.

A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease.

CARMELINA

Currently enrolling participants.

A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcomE study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk.

 

« Clinical Research Home | Meet the Team »
Back to top
sidebar image

Quick Links

 

Meet the Team »

 

Contact Us

Debbie Weeks, Research Associate
1-855-228-0832
1-509-358-7733